GAGE2B: A Potential Drug Target for Cancer and Testis Antigens

Target Name: GAGE2B

NCBI ID: G645037

GAGE2B

GAGE2B: A Potential Drug Target for Cancer and Testis Antigens

GAGE2B (cancer/testis antigen 4.2) is a protein that is expressed in various tissues, including the brain, spleen, and Peyer's patches of the intestine. It is a glycoprotein with a molecular weight of approximately 180 kDa. GAGE2B is known to be involved in the immune response and has been implicated in the development and progression of several types of cancer, particularly ovarian and testicular cancers.

GAGE2B as a Cancer and Testis Antigen

GAGE2B has been shown to be expressed in a variety of cancer types, including breast, ovarian, and prostate cancer. In ovarian cancer, GAGE2B has been shown to be overexpressed in the primary and metastatic stages of disease. Studies have also shown that GAGE2B is present in the testes and that its expression is increased in testicular cancer compared to normal tissue.

GAGE2B as a Potential Drug Target

GAGE2B's involvement in cancer development and progression makes it a potential drug target. One approach to targeting GAGE2B is to use small molecules that can modulate its expression and activity. For example, inhibitors of the GAGE2B-activated protein kinase (GAPK) have been shown to be effective in inhibiting the growth and survival of ovarian cancer cells. Similarly, inhibitors of GAGE2B's downstream target, the transcription factor Pax4, have also been shown to be effective in inhibiting the growth and survival of ovarian cancer cells.

Another approach to targeting GAGE2B is to use antibodies that can specifically recognize and target GAGE2B on cancer cells. This approach has been shown to be effective in inhibiting the growth and survival of ovarian cancer cells.

GAGE2B as a Biomarker

GAGE2B has also been shown to be a potential biomarker for cancer. The expression of GAGE2B has been shown to be associated with the development of several types of cancer, including ovarian and testicular cancers. Additionally, studies have shown that GAGE2B can be used as a diagnostic marker for cancer, with higher expression of GAGE2B in cancer cells compared to normal tissue.

Conclusion

GAGE2B is a protein that is involved in the immune response and has been implicated in the development and progression of several types of cancer, particularly ovarian and testicular cancers. As a potential drug target and biomarker, GAGE2B is a promising target for the development of new cancer therapies. Further research is needed to fully understand the role of GAGE2B in cancer and to develop effective strategies for targeting it.

Protein Name: G Antigen 2B

Functions: Antigen, recognized on melanoma by autologous cytolytic T-lymphocytes

The "GAGE2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAGE2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets